Founder Eric Schwarz interviewed on ABC7 Eyewitness News



Eric discusses with ABC 7 Eyewitness News his role as a participant with UCI researchers in an ongoing Phase 3 clinical trial being conducted by Israeli pharma company Brainstorm's NUROWN stem-cell therapy that hopes to slow the progression of ALS

Learn More >>

By |April 4th, 2018|

BrainStorm Cell Therapeutics’ Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients



NEW YORK and PETACH TIKVAH, Israel, March 28, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announces that it has amended the protocol of its Phase 3 clinical trial of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS). Per the protocol amendment, Canada-based ALS patients may now enroll in the ongoing Phase 3 NurOwn clinical trial.

Learn More >>

By |April 4th, 2018|